Zimmer Biomet’s (NYSE:ZBH) Buy Rating Reiterated at BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report issued on Tuesday, January 30th. They currently have a $144.00 price objective on the medical equipment provider’s stock.

Other equities research analysts have also issued reports about the stock. Goldman Sachs Group raised shares of Zimmer Biomet from a sell rating to a neutral rating and set a $125.00 price objective on the stock in a report on Tuesday, December 19th. Stifel Nicolaus upgraded shares of Zimmer Biomet from a hold rating to a buy rating and boosted their target price for the company from $120.00 to $168.00 in a research report on Wednesday, January 31st. Canaccord Genuity restated a hold rating and set a $132.00 target price on shares of Zimmer Biomet in a research report on Friday, January 5th. Robert W. Baird restated a buy rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Finally, TheStreet downgraded shares of Zimmer Biomet from a b- rating to a c+ rating in a research report on Friday, November 24th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $141.67.

Zimmer Biomet (ZBH) traded up $0.95 during midday trading on Tuesday, reaching $118.65. 337,815 shares of the company’s stock traded hands, compared to its average volume of 1,488,281. The company has a quick ratio of 0.83, a current ratio of 1.52 and a debt-to-equity ratio of 0.76. Zimmer Biomet has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The stock has a market capitalization of $23,472.71, a price-to-earnings ratio of 13.06, a P/E/G ratio of 2.04 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.14 earnings per share. analysts forecast that Zimmer Biomet will post 7.82 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.81%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 10.65%.

In other news, VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.07% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in ZBH. Bank of Nova Scotia Trust Co. purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at $112,000. FNY Managed Accounts LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at $117,000. BB&T Investment Services Inc. purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at $144,000. Cerebellum GP LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at $133,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at $140,000. Institutional investors and hedge funds own 86.36% of the company’s stock.

WARNING: This piece was first published by Week Herald and is the property of of Week Herald. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://weekherald.com/2018/02/15/zimmer-biomets-zbh-buy-rating-reaffirmed-at-bmo-capital-markets.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply